A protocol for precise comparisons of small vessel disease lesions between ex vivo magnetic resonance imaging and histopathology

Catherine A Humphreys1,2, Maurits A Jansen2, Susana Muñoz Maniega2,3, Víctor González-Castro4, Cyril Pernet2,3, Ian J Deary2,5, Rustam Al-Shahi Salman2, Joanna M Wardlaw2,3 and Colin Smith1,2

Introduction

Sporadic human cerebral small vessel disease (SVD) is common, causing 25% of all ischemic strokes,1 85% of all intracerebral haemorrhage2 and vascular dementia. SVD is seen in at least 56.5% of Alzheimer’s disease3 and synergistically worsens symptoms.4 Although the neuroradiological characterization of SVD lesions has been standardized,5 similar approaches are needed in pathological assessment of SVD, and the...
pathological basis of radiological lesions remains poorly understood.

Pathological studies are not dynamic. They are limited to tissue taken at the time of death. Much of the pathological literature has focused on the lacune, which is relatively easily identified at autopsy, but is descriptive. Attempting to understand the pathophysiology is difficult; pathological studies, especially with imaging correlations, are few, with little information on histopathological changes in and around SVD lesions seen on imaging and whether lesions vary by brain region. Systematic reviews of studies comparing post-mortem imaging and histology appearances reveal just three studies correlating microbleeds identified on magnetic resonance imaging (MRI) with histopathology in SVD in 15 cases, while one other paper described three cases with at least three microbleeds. Five papers studied lacunes: 2 with 59 lacunes in 18 cases, one with four cases and at least four lacunes, one with two cases and unknown numbers of lacunes and one study describing lacune appearances without any details of numbers of cases or lesions. There are greater numbers of studies looking at white matter hyperintensities (WMH), but their pathophysiology has not yet been fully elucidated.

All previous post-mortem studies aiming to characterize SVD lesion appearances image whole brains, whole hemispheres or brain slices (manuscript in preparation). Some studies have attempted to provide more detailed localization by scanning both whole brains and individual macroscopic coronal brain slices. This is of value when assessing overall disease burden, but lesion locations are typically approximated using gross landmarks or tissue is sampled broadly from areas identified on imaging, precluding accurate comparison of individual lesions. As such these studies cannot confidently correlate histology with imaging. This may, at least partly, explain the limited understanding of SVD pathogenesis, the lesion heterogeneity at a cellular level, and the modest associations described so far between imaging and clinical features.

We developed a protocol to precisely compare the histological and radiological features of SVD in human post-mortem brain tissue, to test the hypothesis that different SVD lesions identified and defined on MRI represent specific histological, lesions. We aim to use this information to define the histological lesions of SVD and compare it to clinical and in vivo radiological data. In the future we will further explore the pathophysiological mechanisms using targeted genetic studies, with the intention of ultimately being able to refine SVD animal models and identify therapeutic targets and preventative strategies.

Methods

Design

This is a prospective observational study using tissue from three cohorts representing severe SVD (Lothian study of INtraCerebral Haemorrhage, Pathology, Imaging and Neurological Outcome, LINCHPIN), normal aging (Lothian Birth Cohort 1936, LBC1936; range from normal to severe SVD, including lesions in evolution) and controls (no or only mild SVD) within the Medical Research Council (MRC) Edinburgh Brain Bank.

Study population

Inclusion criteria

- LINCHPIN and LBC1936 defined by specific cohort criteria.
- Controls: sudden, unexpected, non-suspicious deaths with no known neurological disease in life.

Exclusion criteria

- Time from death to autopsy >5 days.
- Next of kin decline authorization.

Post-mortem neuropathological examination. A standard neuropathological post-mortem examination is carried out by at least one neuropathologist according to Brain Bank protocols (unpublished), extended for this study to include areas typically affected by SVD on MRI. The brain is weighed, the cerebellum and brainstem are removed and 1 cm thick coronal sections are made. The cerebellum is sliced sagittally and the brainstem axially. Samples approximately 2 × 2 × 1 cm are taken from defined neuroanatomical areas (Table 1). Tissue from the left cerebral hemisphere only is used, as SVD is usually considered symmetrical. The right hemisphere will also be studied in 10% of cases, randomly chosen, to ensure this symmetry is true in our population. Each sample is bisected in the same plane as it was cut; one piece is placed in a plastic cassette and fixed in 10% unbuffered formalin in a plastic tube for 24–72 hours before MR scanning and histology (Figure 1). The complementary sample is frozen in nitrogen vapor for long-term storage at −150°C to support future research applications.

Post-mortem magnetic resonance imaging. Through pilot work, we developed the most practical approach to satisfy both our requirements to make precise histopathological comparisons and to obtain excellent
quality images. To minimize air bubble artefact, the lid of the container is secured under formalin cover and left to stand for 5 minutes, it is tapped to release trapped air and then the lid is re-secured under formalin. The

cassettes are held by pieces of plastic at the sides with empty cassettes at each end to prevent movement.

The tissue is scanned overnight in a 7T small-bore rodent MRI scanner (Agilent Technologies, Yarnton, UK) equipped with a 400 mT/m gradient insert with sequences similar to those used in vivo to detect evidence of SVD (Table 2). The long acquisition time (135 minutes) increases sensitivity to small subtle features. For all scans (except the scout), the field of view is $60 \times 60$ mm, the slice thickness is 1 mm with no gap orientated axially, resolution $0.23 \times 0.23 \times 1.0$ mm, 30 slices are obtained across the cassettes containing the tissue. For the scout scan, the field of view is $120 \times 120$ mm, slice thickness 2 mm with a 2 mm gap in three planes. Shimming is done on the entire plastic container using an automated routine for global shimming followed by manual adjustment of the shim coils. This optimizes the homogeneity of the magnetic field to avoid artefact on images. Quality of shim was checked by measuring the 50% linewidth of the H2O peak in an unlocalized $^1$H spectrum. Typical values were 50–60 Hz.

We are not aware of any established grading systems for imaging tissue blocks and grading the SVD burden therein. We have therefore adapted existing protocols for assessing SVD in whole brain MRI\textsuperscript{5} which were developed, validated and applied in our studies of SVD including LBC1936 and LINCHPIN,\textsuperscript{29–31} and have been tested in these studies over the past two decades. Our existing protocols for assessing SVD on MRI are now included in international standard definitions.\textsuperscript{5}

### Table 1. Areas affected by maximal radiological SVD in life selected for MR-histology comparison

| Areas studied                                                                 |
|-------------------------------------------------------------------------------|
| • Anterior frontal parasagittal cortex (BA9)                                  |
| • Broca's area (BA44/45)                                                      |
| • Temporal tip (BA38)                                                         |
| • Frontal, temporal, parietal, and occipital white matter                      |
| • Caudate nucleus                                                             |
| • Basal ganglia                                                               |
| • Hippocampus                                                                 |
| • Hypothalamus                                                                |
| • Thalamus                                                                    |
| • Cerebellum                                                                  |
| • Pons                                                                        |
| • Medulla                                                                    |

BA: Brodmann area.

---

**Figure 1.** Small tissue samples are placed in plastic cassettes for standard histological processing (a). Eight cassettes are stacked in a plastic container and fixed (b) before scanning in a small bore 7T MRI scanner (c) (gradient echo scout). Tissue is only placed in the cassettes where the gradient coil is mostly linear, empty cassettes at each end and folded plastic along the length of the stack prevent movement within the container.
Disease burden assessment on MR and histology is performed independently and blinded to clinical and all other data.

**Histology.** After scanning, the formalin-fixed tissue is paraffin-embedded in its entirety and sections are stained based on previously published data from histological and imaging literature to assess the gliovascular unit and general neuroinflammatory and glial responses (Table 3). SVD burden, Alzheimer’s disease pathology, α-synuclein and amyloid angiopathy are graded using published, validated systems. Slides are digitally scanned using the Xeiss Axioscan system.

**Image registration and analysis.** The MR slice that best matches the histology section is selected visually, and the corresponding slice for each MR sequence is transformed into NIfTI format.

The size of the histology image varies but is of the order of 10–20 thousand pixels in each dimension. To facilitate registration, they are rescaled by a factor of 1/20 using a Mitchell–Netravali kernel and converted to grey levels. To ensure successful registration, the histology images need to be reoriented to match roughly the position of MR images, which might involve flipping the image around the x or y axis. The histology samples are cut to be approximately rectangular in shape and kept in alignment with the rectangular cassettes. Due to the standardized nature of the histological processing methods, there are only a limited number of opportunities for it to be manipulated and rotated away from the position in which it was scanned. Therefore, there are only four possible orientations of the histology sample. The reorientation is done automatically by creating the four possible orientations of the histology image (original, flipped in x, flipped in y, flipped in x and y), registering each to the T1-weighted image (detailed below) and calculating a similarity score (normalized mutual information) between the histology and MR in each case. The highest similarity score corresponds to the best match between histology and the T1-weighted and therefore permits automatic selection of the correct histology orientation. An image with the outline of the MR overlaid on the histology is produced for each sample to enable a rapid visual confirmation of whether the registration has been successful (Figure 2). The automatic reorientation gives a satisfactory registration in >85% of the cases, in the cases where it fails, the histology is reoriented manually before registration, which then completes successfully.

Automatic registration of MR to each histology image is performed as follows. First, the T1-weighted image is used to create a binary mask of the tissue using k-means clustering with three clusters. The binary mask was created by setting the pixels in the cluster of the maximum center to 1 and the remaining pixels in the image to zero. This mask is applied to all MR images to exclude background signal and then cropped to the minimum field-of-view containing the tissue.

### Table 2. MR imaging sequences and their parameters

| Sequence | Scout | T2  | T2* | T1  | FLAIR |
|----------|-------|-----|-----|-----|-------|
| Type     | GE    | FSE | GE  | FSE | FSE   |
| TE (ms)  | 3.9   | 53  | 22  | 9.2 | 40    |
| TR (ms)  | 23.3  | 2500| 801 | 700 | 8000  |
| TI (ms)  |       |     |     |     | 1816  |
| Flip angle (°) | 20 | 90/180 | 20 | 90/180 | 90/180 |
| Echo spacing (ms) | 13.25 |       |     | 20 |
| Echo train length |       | 4 |     | 2 |
| Band width (Hz) | 52k | 78k | 50k | 100k | 50k |
| Matrix   | 256 × 256 | 256 × 256 | 256 × 256 | 256 × 256 | 256 × 256 |
| NEX      | 2     | 8   | 6   | 4   | 4     |
| Acquisition time (minutes) | 0.2 | 21.3 | 20.5 | 12 | 68.4 |

FLAIR: fluid attenuated inversion recovery; GE: gradient echo; FSE: fast spin echo; TE: echo time; TR: repetition time; TI: inversion time; NEX: number of signal averages.
Linear registration is then performed between the T1-weighted and histology images using NiftyReg over five levels of progressively finer resolution, with default settings. The transformation obtained is applied to the other MR modalities of the same slice, to obtain their registered versions (Figure 2). All registered MR images and the resampled histology are then saved in NIfTI format for visualization (MRIcro40). All processing is performed in R (v. 3.4) within RStudio (v. 1.0), using the packages “jpeg”, “divest”, “mmand”, “RNifti”, and “RNiftyReg”. The registered images are visualized and SVD lesions identified and described during grading are selected in one modality and automatically identified in the other.

Table 3. Special stains and immunohistochemical stains used for assessment of SVD, vascular and neurodegenerative pathology

| Stains                            | Concentration | Antigen retrieval       | Manufacturer                        | Feature assessed                                  |
|----------------------------------|---------------|-------------------------|-------------------------------------|--------------------------------------------------|
| Cut at 4 μm                      |               |                         |                                     |                                                  |
| BA4                              | 1:100         | Formic acid             | Dako, Glostrup, Denmark, M0872      | Amyloid plaques, cerebral amyloid angiopathy      |
| Tau                              | 1:2500        | None                    | Thermo Fisher Scientific, Illinois, US, MN1020 | Neurofibrillary tangles                          |
| α-Synuclein                      | 1:200         | Pressure cooker and citric acid | Thermo Fisher Scientific, Illinois, US, AHB0261 | Lewy bodies                                     |
| Myelin basic protein             | 1:500         | Formic acid             | Abcam, Ab77895                      | Myelin                                           |
| Neurofilament heavy              | 1:500         | Citric and formic acid  | Abcam, Ab8135                       | Axons                                            |
| CD163                            | 1:1000        | Pressure cooker and citric acid | Abcam, Ab87099                     | Macrophages                                      |
| Claudin-5                        | 1:250         | Pressure cooker and citric acid | Abcam, Ab15106                     | Endothelial tight junctions                      |
| Collagen-1                       | 1:1000        | Pressure cooker and citric acid | Abcam, Ab90395                     | Vascular media                                   |
| Platelet-derived growth factor receptor β | 1:100 | Pressure cooker and citric acid | Abcam, Ab32570                     | Pericytes                                        |
| Smooth muscle actin              | 1:1000        | Pressure cooker and citric acid | Dako, Glostrup, Denmark, M0851     | Vascular smooth muscle                           |
| CD68                             | 1:100         | Pressure cooker and citric acid | Dako, Glostrup, Denmark, M0876     | Activated microglia                              |
| Gliarial fibrillary acidic protein| 1:800         | None                    | Dako, Glostrup, Denmark, Z0334      | Astrocytes                                       |
| Cut at 6 μm                      |               |                         |                                     |                                                  |
| H&E                              |               |                         |                                     | General structure                                 |
| Masson trichrome                 |               |                         |                                     | Connective tissue                                 |
| Luxol fast blue                  |               |                         |                                     | Myelin                                           |
| Perl's                           |               |                         |                                     | Iron                                             |

H&E: hematoxylin and eosin.
which allows accurate for characterization and comparison across all MR sequences and histological stains (Figures 2 and 3).

Scanning is done overnight on two consecutive nights, the registration is automated and lesion comparison takes several hours, depending on the number of lesions identified. The whole process from autopsy to lesions being compared takes about one week.

Both MR and histology quality are excellent; histology, in particular is unaffected by the scanning process (examples in Figures 2 and 3).

In establishing this protocol, we have carefully considered how to minimize bias. All consecutive cases donated to the brain bank that meet the specific cohort and brain bank criteria are coded and processed using standardized procedures. Cases are batched until
there are between 5 and 10, which are then rated at the same time. MR and histology ratings are carried out independently, blinded to cohort, clinical data and all other diagnoses and are based on validated guidelines as far as possible. A proportion of ratings will be carried out by a second experienced reviewer, and after a period of time repeated by the original reviewer, to allow inter- and intra-rater scores, respectively, to be calculated.

Study outcomes

Primary outcomes

- Identify and define the pathological lesions of SVD on tissue sections, in relation to the lesions seen on neuroimaging.

Secondary outcomes

- Further understanding of gliovascular unit abnormalities from protein expression studies using additional stains and immunohistochemistry.
- Group cases by SVD severity as graded on MRI and histology for future assessment of protein and gene expression.
- Develop a reproducible protocol that can be adapted to study clinical–radiological–pathological correlations in other neurological diseases.

Estimates of likely numbers of cases. We estimate that about 18 brains will be donated and can be scanned per annum for all three cohorts in total, based on...
previous years. We began scanning in 2015 and have carried out this protocol in 53 cases so far; 21 severe SVD, 9 normal aging and 23 controls. Of these, 25 have also had in vivo MRI or CT brain imaging (17 severe SVD, 8 normal aging). In comparison with existing literature, this sample is one of the largest to date, and the only one to precisely and systematically study the areas most affected by SVD on in vivo imaging. It will allow for much greater depth of analysis regarding, for example, spatial variation in lesions, perilesional changes and severity of lesions. Numbers will increase as we continue to scan cases and include new cohorts; a population with symptomatic lacunar stroke\textsuperscript{46} and a subgroup of the Scottish Dementia new cohorts; a population with symptomatic lacunar stroke\textsuperscript{46} and a subgroup of the Scottish Dementia Research Interest Register\textsuperscript{47} with Alzheimer’s disease have recently been added.

**Statistical analyses.** Specific statistical analyses will depend on the distribution of the data; they will include descriptive statistics for lesion prevalence and appearances, and regression analyses for differences between groups. We will choose a number of relevant features to study from the rich clinical, imaging and histological data available.

For example, LBC1936 subjects have serial research-standard MRI in life with detailed assessment of SVD features including quantitative structural and functional analysis, medical histories and cognitive information from age 11 to the 8th decade.\textsuperscript{26,29} LINCHPIN includes current cognition, medical history and recent in vivo imaging. This will enable us to study associations where information is currently missing; such as the burden of SVD lesions visible in life and the prevalence of matrix protein abnormalities; the relationship between perivascular space visibility on MRI and numbers of active microglia; and confirm if the health of the myelin and axons in apparently normal tissue varies with the severity of WMH as is suggested by in vivo MRI.\textsuperscript{48} Control cases have medical and social history available. However, by definition they have had no neurological disease in life, have no cognitive impairment and therefore do not have in vivo imaging. We will be able to compare these data to the extent and severity of SVD assessed on the ex vivo imaging and histology. The extent of the analyses will be decided based on the final number of cases obtained. Inter-rater reliability will be assessed using weighted Kappa statistics.

After MRI and histology images are fully assessed, cases will be stratified into groups with and without cognitive impairment, by medical history and SVD burden, from none to severe. We will use the complementary frozen tissue to make targeted studies of gene expression differences between the groups. In particular, the short tissue fixation period retains RNA and DNA integrity supporting novel techniques such as BaseScope, a modified, quantifiable in situ hybridization technique identifying transcripts at a single cell level.\textsuperscript{49}

**Data monitoring body, study organization, funding and ethics.** CAH is funded by an Alzheimer’s Society Clinical Training Fellowship, and pilot work was supported by a Princess Margaret Research Development Fellowship through the Stroke Association. Post-mortem MR scanning was supported by a pilot grant from the MRC Centre for Cognitive Ageing and Cognitive Epidemiology and the Scottish Imaging Network (MRC Grant No. MR/K026992/1), A Platform for Scientific Excellence (SINAPSE) Initiative. JMW is supported by the EU H2020 PHC-03-15 project no 666881, SVD@s@Target and Fondation Leducq project 16 CVD 05. IJD is supported by the Centre for Cognitive Ageing and Cognitive Epidemiology, which is funded by the MRC (Grant No. MR/K026992/1) and Biotechnology and Biological Research Council. The Lothian Birth Cohort 1936 is funded principally by Age UK (Disconnected Mind programme), and also the MRC (MR/M01311/1).

Informed consent is obtained from all participants in the severe SVD (ethical approval from Scotland A Research Ethics Committee ref. 10/MRE00/23) and normal aging cohorts in life (Multi-Centre Research Ethics Committee for Scotland MREC/01/0/56, Lothian Research Ethics Committee LREC/2003/2/29 and Scotland A Research Ethics Committee 07/ MRE00/58, REC REF AM17, 07/MRE00/58/AM14).

Post-mortem authorization is also obtained from next of kin for all cases. The MRC Edinburgh Brain Bank has full ethical approval and consent for the use of tissue in research (East of Scotland Research Ethics Service, ref 16/ES/0084) and works within the framework of the Human Tissue (Scotland) Act 2006. It has a local management group and a steering committee, both of which include lay representation.

**Discussion**

In our current study, two cohorts, LBC1936 and LINCHPIN, have several important complementary characteristics relevant to SVD; and other cohorts are now being added. The MRC Edinburgh Brain Bank is a responsive tissue resource, ensuring tissue is fit for end-user needs, developed around existing clinical cohorts, with high brain donation rates within the clinical cohorts.\textsuperscript{27,50} We employ targeted sampling with all residual tissue being returned to the body, as donation of small tissue samples is less distressing to relatives than whole organs.\textsuperscript{51} The Edinburgh Brain Bank is part of the UK Brain Bank Network, a coordinated group who have developed minimum diagnostic
datasets, tissue handling protocols, and ethical and governance standards across multiple UK brain banks. Data linkage is key to maximizing this resource, and targeted post-mortem MRI adds to the data generated from each individual case.

We encountered several issues while developing this protocol. Air bubbles within the tissue and plastic cassettes cause MR artefact and may be mistaken for, or mask, microbleeds on T2* sequences making it important to minimize their presence, as described. Previous studies did not precisely match lesions on MR with histological images due to differing slice thicknesses and resolutions. We obtain serial 1 mm MR slices through each tissue block, although this is of a different order of thickness to the histological sections (mm versus microns). To make the most accurate comparison, the MR images are compared to corresponding histological images and the most complementary are registered. Formalin fixation of human brain tissue alters the MR properties of the tissue with time as the formalin diffuses into it. The use of small samples minimizes the difference in fixation between the deep and superficial tissue. T2 values of human brain tissue change with duration of fixation but plateau between 10 hours and five weeks. We have standardized tissue fixation to minimize fixation-induced variability between MR images. At 7T, tissue is vulnerable to overheating, which impairs tissue quality. Brain absorbs more radiofrequency than other tissues and our samples are in a relatively small amount of formalin without in vivo mechanisms, such as vasodilation, to dissipate heat. The scanner bore is cooled to 22.6°C but this may not be sufficient. Our scanning protocols have been designed to maximize anatomic resolution and increase the signal to noise ratio while avoiding overheating. Temperature monitoring during scanning showed a maximum 1.8°C rise within the plastic tube, which would not affect tissue quality and heat artefact has not been observed on histological examination.

As with many post-mortem studies, the number of cases available for study is relatively small. However, our study is one of the largest detailed post-mortem studies of SVD, and benefits from detailed data linkage and well-characterized cohorts. In addition, we employ extensive sampling of each case, targeting areas particularly affected by SVD and retaining complimentary frozen tissue for further interrogation with genomic technologies. The specific areas studied may be refined in future depending on the specific disease or characteristic under investigation. Pilot work within our lab has shown that formalin fixed paraffin-embedded tissue is not suitable for post-mortem imaging so retrospective imaging of cases with paraffin-embedded tissue is not possible. However, the histological protocol developed from the combined radiological–histological assessment could be applied retrospectively to appropriate tissue within the Brain Bank with relevant clinical data, thereby further extending the sample size for future related work using biochemical and genetic methods.

SVD lesions are well characterized on neuroimaging and described on neuropathology (although not consistently); however, attempts to correlate the appearances have found only modest associations. This may reflect variation in methodologies or true variation as suggested in rodent models where it appears SVD may result from multiple minor defects in different components of the neurovascular unit which we aim to study further with this protocol and future work. As a static assessment of a dynamic disease process, histopathological assessment may be limited; lesions at post-mortem in elderly patients are often end-stage. However, longitudinal assessments in life allow plotting of disease trajectories, and our initial work shows a gradation from subclinical, to lesions-in-evolution to severe lesions which will further inform interpretation of SVD pathophysiology. WMH in particular may be more dynamic than previously appreciated. Histopathological studies in humans have found protein expression abnormalities within the gliovascular unit in subjects with WMH and in vivo imaging suggests blood–brain barrier (BBB) dysfunction and leakiness. Alterations in the gliovascular unit are seen in an animal model prior to the onset of recordable hypertension.

Summary and conclusions
This protocol describes a new method to precisely assess and compare lesion appearances between brain MRI and histopathology to validate in vivo MRI findings in and around SVD lesions, aiming to increase our understanding of SVD pathophysiology and facilitate a meaningful clinical and radiological diagnosis. These methods and tissue may also be used in other conditions where the pathophysiology is poorly understood such as autism or the neurological effects of type 2 diabetes mellitus, and to validate clinical and radiological assessments and diagnoses.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Victor González-Castro http://orcid.org/0000-0001-8742-3775
Joanna M Wardlaw http://orcid.org/0000-0002-9812-6642
References

1. Sudlow CL and Warlow CP. Comparable studies of the incidence of stroke and its pathological types: Results from an international collaboration. International Stroke Incidence Collaboration. Stroke 1997; 28: 491–499.

2. Samarasekera N, Fonville A, Lerpiniere C, et al. Influence of intracerebral hemorrhage location on incidence, characteristics, and outcome: Population-based study. Stroke 2015; 46: 361–368.

3. Jellinger KA and Attems J. Incidence of cerebrovascular lesions in Alzheimer’s disease: A postmortem study. Acta Neuropathol 2003; 105: 14–17.

4. Smallwood A, Oulhaj A, Joachim C, et al. Cerebral subcortical small vessel disease and its relation to cognition in elderly subjects: A pathological study in the Oxford Project to Investigate Memory and Ageing (OPTIMA) cohort. Neuropathol Appl Neurobiol 2012; 38: 337–343.

5. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12: 822–838.

6. Fisher CM. Lacunar strokes and infarcts: A review. Neurology 1982; 32: 871–876.

7. Bailey EL, Smith C, Sudlow CL and Wardlaw JM. Pathology of lacunar ischemic stroke in humans – a systematic review. Brain Pathol 2012; 22: 583–591.

8. Gouw AA, Seewann A, van der Flier WM, et al. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011; 82: 126–135.

9. Pantoni L and Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke 1997; 28: 652–659.

10. Murray ME, Vemuri P, Preboske GM, et al. A quantitative postmortem MRI design sensitive to white matter hyperintensity differences and their relationship with underlying pathology. J Neuropathol Exp Neurol 2012; 71: 1113–1122.

11. Shoomanesh A, Kwok CS and Benavente O. Cerebral microbleeds: histopathological correlation of neuroimaging. Cerebrovasc Dis 2011; 32: 528–534.

12. Fazekas F, Kleinert R, Roob G, et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol 1999; 20: 637–642.

13. Tatsumi S, Shihohara M and Yamamoto T. Direct comparison of histology of microbleeds with postmortem MR images: a case report. Cerebrovasc Dis 2008; 26: 142–146.

14. Schrag M, McAuley G, Pomakian J, et al. Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study. Acta Neuropathol 2010; 119: 291–302.

15. Tanaka A, Ueno Y, Nakayama Y, Takano K and Takebayashi S. Small chronic hemorrhages and ischemic lesions in association with spontaneous intracerebral hematomas. Stroke 1999; 30: 1637–1642.

16. Bokura H, Kobayashi S and Yamaguchi S. Distinguishing silent lacunar infarction from enlarged Virchow–Robin spaces: a magnetic resonance imaging and pathological study. J Neurol 1998; 245: 116–122.

17. Braffman BH, Zimmerman RA, Trojanowski JQ, Gonatas NK, Hickey WF and Schlaepfer WW. Brain MR: pathologic correlation with gross and histopathology. I. Lacunar infarction and Virchow–Robin spaces. AJR Am J Roentgenol 1988; 151: 551–558.

18. Revesz T, Hawkins CP, du Boulay EP, Barnard RO and McDonald WJ. Pathological findings correlated with magnetic resonance imaging in subcortical arteriosclerotic encephalopathy (Binswanger’s disease). J Neurol Neurosurg Psychiatry 1989; 52: 1337–1344.

19. Pullicino PM, Miller LL, Alexandrov AV and Ostrow PT. Infrarapatal ‘lacunes’. Clinical and pathological correlations. Stroke 1995; 26: 1598–1602.

20. Matsusue E, Sugihara S, Fujiji S, Ohama E, Kinoshita T and Ogawa T. White matter changes in elderly people: MR-pathologic correlations. Magn Reson Med Sci 2006; 5: 99–104.

21. Wardlaw JM, Valdes Hernandez MC and Munoz-Maniega S. What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. J Am Heart Assoc 2015; 4: 001140.

22. Lin J, Wang D, Lan L and Fan Y. Multiple factors involved in the pathogenesis of white matter lesions. BioMed Res Int 2017; 2017: 9372050.

23. Scarpelli M, Salvolini U, Diamanti L, Montironi R, Chiaromoni L and Maricotti M. MRI and pathological examination of post-mortem brains: the problem of white matter high signal areas. Neuroradiology 1994; 36: 393–398.

24. Awad IA, Johnson PC, Spetzler RF and Hodak JA. Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. II. Postmortem pathological correlations. Stroke 1986; 17: 1090–1097.

25. Chinowitz MI, Estes ML, Furlan AJ and Awad IA. Further observations on the pathology of subcortical lesions identified on magnetic resonance imaging. Arch Neurol 1992; 49: 747–752.

26. Deary IJ, Gow AJ, Pattie A and Starr JM. Cohort profile: the Lothian Birth Cohorts of 1921 and 1936. Int J Epidemiol 2012; 41: 1576–1584.

27. Samarasekera N, Lerpiniere C, Fonville AF, et al. Consent for brain tissue donation after intracerebral haemorrhage: a community-based study. PLoS One 2015; 10: e0135043.

28. Deary IJ, Gow AJ, Taylor MD, et al. The Lothian Birth Cohort 1936: a study to examine influences on cognitive ageing from age 11 to age 70 and beyond. BMC Geriatr 2007; 7: 28.

29. Wardlaw JM, Bastin ME, Valdes Hernandez MC, et al. Brain aging, cognition in youth and old age and vascular disease in the Lothian Birth Cohort 1936: rationale, design and methodology of the imaging protocol. Int J Stroke 2011; 6: 547–559.

30. Wardlaw JM, Doubal F, Armitage P, et al. Lacunar stroke is associated with diffuse blood–brain barrier dysfunction. Ann Neurol 2009; 65: 194–202.
31. Valdes Hernandez Mc D, Armitage PA, Thrippleton MJ, et al. Rationale, design and methodology of the image analysis protocol for studies of patients with cerebral small vessel disease and mild stroke. Brain Behav 2015; 5: e00415.
32. Deramecourt V, Slade JY, Oakley AE, et al. Staging and natural history of cerebrovascular pathology in dementia. Neurology 2012; 78: 1043–1050.
33. Braak H and Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239–259.
34. Thal DR, Rub U, Orantes M and Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791–1800.
35. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863–1872.
36. Love S, Chalmers K, Ince P, et al. Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. Am J Neurodegener Dis 2014; 3: 19–32.
37. Mitchell DN and Netravali AN. Reconstruction filters in computer graphics. Comput Graph 1988; 22: 221–228.
38. Hartigan JW and Wong MA. Algorithm AS 136: a K-Means clustering algorithm. J R Stat Soc 1979; 28: 100–108.
39. Modat M, Ridgway GR, Taylor ZA, et al. Fast free-form deformation using graphics processing units. Comput Methods Prog Biomed 2010; 98: 278–284.
40. Rorden C and Brett M. Stereotaxic display of brain lesions. Behav Neurol 2000; 12: 191–200.
41. Urbanek S. jpeg: read and write JPEG images [Internet]. https://cran.r-project.org/package=jpeg2014 (accessed 18 October 2017).
42. Clayden J. mmand: mathematical morphology in any number of dimensions [Internet]. https://cran.r-project.org/package=mmand2017 (accessed 18 October 2017).
43. Clayden JMM, Presles B, Anthopoulos T and Daga P. RNiftyReg: image registration using the NiftyReg library [Internet]. http://cran.r-project.org/package=RNiftyReg 2015 (accessed 1 December 2016).
44. Clayden JRC. divest: get images out of DICOM format quickly [Internet]. R package, https://cran.r-project.org/package=divest2017 (accessed 18 October 2017).
45. Jon Clayden BC, Jenkinson M, Hall M, et al. RNifti: fast R and C++ access to NIfTI images [Internet]. https://cran.r-project.org/package=RNifti2016 (accessed 18 October 2017).
46. Wardlaw JM, Makin SJ, Valdés Hernández MC et al. Blood-brain barrier failure as a core mechanism in cerebral small vessel disease and dementia: evidence from a cohort study. Alzheimer’s Dementia 2017; 13: 634–643.
47. Law E, Connelly PJ, Randall E, et al. Does the Addenbrooke’s cognitive examination-revised add to the Mini-Mental State Examination in established Alzheimer disease? Results from a national dementia research register. Int J Geriatr Psychiatry 2013; 28: 351–355.
48. Maniega SM, Valdes Hernandez MC, Clayden JD, et al. White matter hyperintensities and normal-appearing white matter integrity in the aging brain. Neurobiol Aging 2015; 36: 909–918.
49. Bialas AR, Presumey J, Das A, et al. Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature 2017; 546: 539–543.
50. Henstridge CM, Jackson RJ, Kim JM, et al. Post-mortem brain analyses of the Lothian Birth Cohort 1936: extending lifetime cognitive and brain phenotyping to the level of the synapse. Acta Neuropathol Commun 2015; 3: 53.
51. Ashcroft R. The ethics of reusing archived tissue for research. Neuropathol Appl Neurobiol 2000; 26: 408–411.
52. Medical Research Council. About the UK Brain Banks Network [Internet], 2016. https://mrc.ukri.org/research/facilities-and-resources-for-researchers/brain-banks/about-the-uk-brain-banks-network/ (accessed 10 October 2017).
53. Dawe RJ, Bennett DA, Schneider JA, Vasireddi SK and Arfanakis K. Postmortem MRI of human brain hemispheres: T2 relaxation times during formaldehyde fixation. Magn Reson Med 2009; 61: 810–818.
54. Alafuzoff I, Gelpi E, Al-Sarraj S, et al. The need to unify neuropathological assessments of vascular alterations in the ageing brain: multicentre survey by the BrainNet Europe consortium. Exp Gerontol 2012; 47: 825–833.
55. Bailey EL, McBride MW, Beattie W, et al. Differential gene expression in multiple neurological, inflammatory and connective tissue pathways in a spontaneous model of human small vessel stroke. Neuropathol Appl Neurobiol 2014; 40: 855–872.
56. Chen A, Akinyemi RO, Hase Y, et al. Frontal white matter hyperintensities, clasmatodendrosis and gliovascular abnormalities in ageing and post-stroke dementia. Brain 2016; 139: 242–258.
57. Bailey EL, Smith C, Sudlow CL and Wardlaw JM. Is the spontaneously hypertensive stroke prone rat a pertinent model of sub cortical ischemic stroke? A systematic review. Int J Stroke 2011; 6: 434–444.